Monday, December 06, 2021 5:31:24 PM
Non-trading Preferred shares that convert into trading common shares are typically requested(especially by experienced lending institutions) to have reserved the exact number of common share end total by the TA, whoch then gurantee the total amount of shares are available wothout the lender ever crossing 5% threshold because they can draw down the reserve shares incrementally from their conversion rights. When that reserve happens the OS increases the amount of the issued shares. But does not reflect in the held at DTC number, as they are not in registered float. And it is Even more typical of a Lending Institution to gurantee for themselves the availability of the promised shares to them.
This is not a difficult concept. Why the obfuscation?
And still, why avoid the discussion of the ridiculous Market Cap? Or the $23m cash rasie at $10 per share!
$10 per share!
And those people plan to make handsome returns. Undeniable.
This is not a difficult concept. Why the obfuscation?
And still, why avoid the discussion of the ridiculous Market Cap? Or the $23m cash rasie at $10 per share!
$10 per share!
And those people plan to make handsome returns. Undeniable.
Sometimes its Skil, Sometimes its Luc.
I Appreciate All Member Follows!
Desperate Sellers Become Desperate Buyers. Vice Versa
ALL IMHO.
Recent BRTX News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/13/2026 09:22:23 PM
- BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform • GlobeNewswire Inc. • 04/07/2026 12:15:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/03/2026 06:46:20 PM
- BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease • GlobeNewswire Inc. • 03/30/2026 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2026 08:20:29 PM
- BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease • GlobeNewswire Inc. • 03/19/2026 12:00:00 PM
- BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026 • GlobeNewswire Inc. • 03/05/2026 01:00:00 PM
- BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy • GlobeNewswire Inc. • 03/04/2026 01:00:00 PM
- BioRestorative secures Australian patent protection for ThermoStem® obesity therapy platform • IH Market News • 02/24/2026 03:14:07 PM
- BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs • GlobeNewswire Inc. • 02/24/2026 01:30:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/23/2026 09:50:39 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/18/2026 09:12:24 PM
- BioRestorative Announces Closing of $5.0 Million Public Offering • GlobeNewswire Inc. • 02/14/2026 01:30:00 AM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 02/13/2026 02:48:15 PM
- BioRestorative Announces Pricing of $5.0 Million Public Offering • GlobeNewswire Inc. • 02/12/2026 03:30:00 AM
- BioRestorative Announces Positive Outcome from Type B Meeting with FDA • GlobeNewswire Inc. • 02/11/2026 12:30:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/10/2026 10:20:59 PM
- BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease • GlobeNewswire Inc. • 02/10/2026 01:00:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/09/2026 10:31:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/12/2025 10:11:16 PM
